Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
NVAX
NVAX
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
NVAX News
Moderna's Flu Vaccine Application Rejected by FDA
5d ago
stocktwits
Pfizer Q4 Earnings Preview: Analysts Expect Decline
Feb 02 2026
Benzinga
Novavax Faces Challenges Despite Recent Gains
Jan 29 2026
Fool
Pfizer Shares Rise on Upgraded Price Forecast
Jan 27 2026
Benzinga
Novavax Partners with Pfizer in Key Licensing Deal
Jan 26 2026
Benzinga
Analysts Favor Novavax Over Moderna After $30M Pfizer Licensing Deal
Jan 22 2026
stocktwits
HHS Secretary Robert F. Kennedy Jr. Dismisses Four Childhood Vaccine Advisors, Impacting Vaccine Injury Compensation Program
Jan 20 2026
seekingalpha
Novavax Enters $30M Licensing Agreement with Pfizer for Matrix-M Adjuvant
Jan 20 2026
Benzinga
Novavax Signs $30M Licensing Deal with Pfizer for Matrix-M Adjuvant
Jan 20 2026
stocktwits
Novavax (NVAX) Secures $30M Licensing Deal with Pfizer (PFE) for Matrix-M Adjuvant
Jan 20 2026
seekingalpha
Novavax (NVAX) Enters $30M License Agreement with Pfizer (PFE) for Matrix-M Adjuvant
Jan 20 2026
NASDAQ.COM
Novavax Licenses Matrix-M® Adjuvant to Pfizer for Two Disease Areas
Jan 20 2026
PRnewswire
Novavax Enters $30M Licensing Agreement with Pfizer for Matrix-M®
Jan 20 2026
Newsfilter
Novavax Inc (NVAX) Shares Surge 16.22% Amid Rising Respiratory Illnesses
Jan 13 2026
Benzinga
HHS Secretary Kennedy Appoints Two OB-GYN Experts to CDC's ACIP
Jan 13 2026
seekingalpha
Reasons Behind Moderna's Stock Decline Despite Positive Developments
Jan 12 2026
Barron's
Show More News
